Poster Image
Logo Image
Bgimage
Title
Advancing Every Day
Description
You are focused on the big biological question and are poised to dramatically change millions of lives for the better. Successfully navigating through clinical trials requires a different set of core competencies and capabilities. For 25 years Aldevron has been a catalyst, advancing therapeutic and vaccine development through expert manufacturing, supporting our clients from discovery to commercialization.
1998
- Aldevron Founded by Michael Chambers & John Ballantyne
2000
- GMP-Source Developed
2005
- 10,000 RG Plasmid DNA Released
2009
- Aldevron Madison WI Location Opened
2014
- First GMP Plasmid Released
2016
- Offer Inventoried Research-Grade CAS9 Enzyme
2017
- TA Assoc. Investment
2018
- Fist to Offer Inventory cGMP SpyFi CAS9 Enzyme
- Original GMP Facility Operational
- Fist cGMP mRNA Mfg. & Release
- 100,000 Plasmid DNA Lots Released
2019
- EQT Equity Stake
2020
- Linear Template Mfg. RNA COVID 19 Vaccine
- Exp. Phase 1 of GMP Facility Operational
- Kevin Ballinger joins as CEO
2021
- Phase 2 of GMP Facility Operational (RNA)
- cGMP RNP Mfg. & Release
- Aldevron Madison Campus Expansion & Renovation
- Fargo Advanced Campus Expansion & Renovation
- Aldevron Acquired by Danaher
2022
- Aldevron Acquires Nature Technologies
- Phase 3 of GMP Facility Operational
- >3,500 cGMP Plasmid DNA Lots Released
- 165,000 Plasmid DNA Lots Released
2023
- Phase 4 of cGMP Facility Operational (RNA)
- Aldevron Madison Campus Expansion & Renovation
- Jennifer Meade named President
Explore our Breakthrough Blog
Enhancing Process Rigor and Quality in RNP Manufacturing
Streamlining mRNA Production
Webinar On Demand: CRISPR Cures 2033
style
Sidebar-section